Article thumbnail

Genetic Diversity of Near Genome-Wide Hepatitis C Virus Sequences during Chronic Infection: Evidence for Protein Structural Conservation Over Time

By Hui Li, Austin L. Hughes, Nazneen Bano, Susan McArdle, Stephen Livingston, Heike Deubner, Brian J. McMahon, Lisa Townshend-Bulson, Rachel McMahan, Hugo R. Rosen and David R. Gretch


Infection with hepatitis C virus (HCV) is one of the leading causes of chronic hepatitis, liver cirrhosis and end-stage liver disease worldwide. The genetics of HCV infection in humans and the disease course of chronic hepatitis C are both remarkably variable. Although the response to interferon treatment is largely dependent on HCV genotypes, whether or not a relationship exists between HCV genome variability and clinical course of hepatitis C disease still remains unknown. To more thoroughly understand HCV genome evolution over time in association with disease course, near genome-wide HCV genomes present in 9 chronically infected participants over 83 total study years were sequenced. Overall, within HCV genomes, the number of synonymous substitutions per synonymous site (dS) significantly exceeded the number of non-synonymous substitutions per site (dN). Although both dS and dN significantly increased with duration of chronic infection, there was a highly significant decrease in dN/dS ratio in HCV genomes over time. These results indicate that purifying selection acted to conserve viral protein structure despite persistence of high level of nucleotide mutagenesis inherent to HCV replication. Based on liver biopsy fibrosis scores, HCV genomes from participants with advanced fibrosis had significantly greater dS values and lower dN/dS ratios compared to participants with mild liver disease. Over time, viral genomes from participants with mild disease had significantly greater annual changes in dN, along with higher dN/dS ratios, compared to participants with advanced fibrosis. Yearly amino acid variations in the HCV p7, NS2, NS3 and NS5B genes were all significantly lower in participants with severe versus mild disease, suggesting possible pathogenic importance of protein structural conservation for these viral gene products

Topics: Research Article
Publisher: Public Library of Science
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2006). A target on the move: innate and adaptive immune escape strategies of hepatitis C virus.
  2. (2010). Adverse outcomes in Alaska natives who recovered from or have chronic hepatitis C infection.
  3. (1994). An introduction to information theory.
  4. (2008). Bioinformatic and physical characterizations of genome-scale ordered RNA structure in mammalian RNA viruses.
  5. (2010). Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants.
  6. (2004). Cell-mediated immunity and the outcome of hepatitis C virus infection.
  7. (2008). Clinical significance of elevated alpha-fetoprotein in Alaskan Native patients with chronic hepatitis C.
  8. (2008). Cutting edge: programmed death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: racedependent differences.
  9. (2004). Detection of genome-scale ordered RNA structure (GORS) in genomes of positive-stranded RNA viruses: Implications for virus evolution and host persistence.
  10. (1996). Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
  11. (2004). Epidemiology and risk factors for hepatitis C in Alaska Natives.
  12. (2000). Estimating synonymous and nonsynonymous substitution rates under realistic evolutionary models.
  13. (2007). Evidence for a functional RNA element in the hepatitis C virus core gene.
  14. (1994). Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences.
  15. (2004). Genetic diversity and evolution of hepatitis C virus–15 years on.
  16. (2010). Genetic diversity of hepatitis C virus predicts recurrent disease after liver transplantation.
  17. (2006). Global challenges in liver disease.
  18. (2009). HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/AlbuPA mice.
  19. (2006). Hepatitis C infection in Alaska Natives with persistently normal, persistently elevated or fluctuating alanine aminotransferase levels.
  20. (2005). Hepatitis C virus core variants isolated from liver tumor but not from adjacent non-tumor tissue interact with Smad3 and inhibit the TGF-beta pathway.
  21. (2007). Hepatitis C virus dynamics during natural infection are associated with longterm histological outcome of chronic hepatitis C disease.
  22. (2008). Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C.
  23. (1999). Hepatitis C–global prevalence (update).
  24. (1995). Histological grading and staging of chronic hepatitis.
  25. (2000). HIV Signature and Sequence Variation Analysis.
  26. (2003). Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy.
  27. (1996). Immunopathogenesis of viral hepatitis.
  28. (2009). Intracellular innate immune cascades and interferon defenses that control hepatitis C virus.
  29. (2008). Investigation of putative multisubtype hepatitis C virus infections in vivo by heteroduplex mobility analysis of core/envelope subgenomes.
  30. (2005). Mechanism of action of interferon and ribavirin in treatment of hepatitis C.
  31. (2007). Molecular biology of hepatitis C virus.
  32. (2000). Molecular evolution and phylogenetics.
  33. (2005). Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man.
  34. (1996). Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection.
  35. (1997). Natural history of hepatitis C.
  36. (2008). Near neutrality: leading edge of the neutral theory of molecular evolution.
  37. (2009). Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.
  38. (2009). Nomenclature and numbering of the hepatitis C virus.
  39. (1976). Role of very slightly deleterious mutations in molecular evolution and polymorphism.
  40. (2002). Scoring of chronic hepatitis.
  41. (2008). Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy.
  42. (1986). Simple methods for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions.
  43. (1995). Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 59 non-coding region.
  44. (1983). The neutral theory of molecular evolution.
  45. (2010). Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity.
  46. (1993). Unbiased estimation of the rates of synonymous and nonsynonymous substitution.
  47. (2007). Viral determinants of resistance to treatment in patients with hepatitis C.
  48. (2006). Viruses as quasispecies: biological implications.